The detection of anti-SARS-CoV-2 IgG and IgM in plasma samples from COVID-19 patients by at least 1 of 4 FDA-authorized commercial serology assay kits (specific for S and/or N antigens) was 100% and 18% for anti-SARS-CoV-2 IgG and IgM, respectively, when combining data from all the four assay kits (Supplemental material- Serology test results reported on COVID-19 patients information data sheet.xlsx, which were provided by the supplier, BioIVT). The gene discussed is CD40LG; the disease is COVID-19.